Press Releases
Thu Aug 6, 2026 08:00 am
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Thu Jul 30, 2026 08:00 am
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Fri Jul 10, 2026 08:00 am
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Mon Jul 6, 2026 09:00 am
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
Thu Jun 25, 2026 08:15 am
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
Wed Jun 17, 2026 08:00 am
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Thu Jun 4, 2026 08:00 am
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Wed May 27, 2026 08:00 am
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Thu May 14, 2026 08:00 am